Biogen Cash Flow Statement
NASDAQ: BIIBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Biogen free cash flow
In fiscal 2025, Biogen generated $2.20 billion of operating cash flow and spent $153.8 million on capital expenditures. That left free cash flow of $2.05 billion, a free-cash-flow margin of 20.7% of revenue. Free cash flow was down 24.7% from the prior year's $2.72 billion.
Summary generated from market data by MetaCap's automated system. Methodology
Biogen cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 1.29B | 1.63B | 1.16B | 2.96B | 1.73B | 4.06B | 5.89B | 4.47B | 2.67B | 3.70B |
| Net Income growth (YoY) | -20.79% | +40.53% | -60.78% | +71.43% | -57.45% | -31.04% | +31.62% | +67.56% | -27.75% | +2.85% |
| Depreciation & Amortization | 779.90M | 673.20M | 494.80M | 518.40M | 487.70M | 457.20M | 464.70M | 650.50M | 1.08B | 682.70M |
| Stock-Based Compensation | 290.80M | 291.20M | 264.20M | 254.10M | 238.60M | 198.30M | 182.30M | 157.50M | 128.00M | 154.80M |
| Change in Working Capital | -210.00M | -230.20M | -143.50M | -615.60M | -282.10M | -450.60M | 6.30M | -511.80M | -685.70M | -278.40M |
| Operating Cash Flow | 2.20B | 2.88B | 1.55B | 1.38B | 3.64B | 4.23B | 7.08B | 6.19B | 4.55B | 4.59B |
| Capital Expenditures | -153.80M | -153.70M | -277.00M | -240.30M | -258.10M | -424.80M | -514.50M | -770.60M | -867.40M | -616.10M |
| Investing Cash Flow | -1.37B | -799.20M | -4.10B | 1.58B | -563.70M | -608.60M | 470.50M | -2.05B | -2.96B | -2.48B |
| Share Repurchases | — | 0 | 0 | -750.00M | -1.80B | -6.68B | -5.87B | -4.35B | -1.37B | -1.00B |
| Debt Issued | 1.73B | 0 | 997.20M | 0 | 0 | 2.97B | 0 | 0 | — | — |
| Debt Repaid | -1.75B | -650.00M | -809.90M | 0 | 0 | -1.50B | 0 | -3.20M | -560.90M | -2.70M |
| Financing Cash Flow | -301.90M | -683.50M | 149.30M | -1.75B | -2.09B | -5.27B | -5.86B | -4.47B | -2.38B | -1.05B |
| Net Change in Cash | 531.60M | 1.39B | -2.40B | 1.21B | 990.00M | -1.65B | 1.69B | -330.60M | -792.10M | 1.05B |
| Free Cash Flow | 2.05B | 2.72B | 1.27B | 1.14B | 3.38B | 3.81B | 6.56B | 5.42B | 3.68B | 3.97B |
This table shows 10 annual periods of Biogen's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BIIB's reporting calendar. What is a cash flow statement?